Literature DB >> 21212268

Recovery of small infectious PrP(res) aggregates from prion-infected cultured cells.

Zaira E Arellano Anaya1, Jimmy Savistchenko1, Véronique Massonneau1, Caroline Lacroux1, Olivier Andréoletti1, Didier Vilette2.   

Abstract

Prion diseases are characterized by deposits of abnormal conformers of the PrP protein. Although large aggregates of proteinase K-resistant PrP (PrP(res)) are infectious, the precise relationships between aggregation state and infectivity remain to be established. In this study, we have fractionated detergent lysates from prion-infected cultured cells by differential ultracentrifugation and ultrafiltration and have characterized a previously unnoticed PrP species. This abnormal form is resistant to proteinase K digestion but, in contrast to typical aggregated PrP(res), remains in the soluble fraction at intermediate centrifugal forces and is not retained by filters of 300-kDa cutoff. Cell-based assay and inoculation to animals demonstrate that these entities are infectious. The finding that cell-derived small infectious PrP(res) aggregates can be recovered in the absence of strong in vitro denaturating treatments now gives a biological basis for investigating the role of small PrP aggregates in the pathogenicity and/or the multiplication cycle of prions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21212268      PMCID: PMC3048700          DOI: 10.1074/jbc.M110.165233

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  Characterization of the murine BSE infectious agent.

Authors:  T Manousis; S Verghese-Nikolakaki; P Keyes; M Sachsamanoglou; M Dawson; O Papadopoulos; T K Sklaviadis
Journal:  J Gen Virol       Date:  2000-06       Impact factor: 3.891

Review 2.  Chemistry and biology of prions.

Authors:  S B Prusiner
Journal:  Biochemistry       Date:  1992-12-15       Impact factor: 3.162

3.  Eight prion strains have PrP(Sc) molecules with different conformations.

Authors:  J Safar; H Wille; V Itri; D Groth; H Serban; M Torchia; F E Cohen; S B Prusiner
Journal:  Nat Med       Date:  1998-10       Impact factor: 53.440

4.  Disruption of prion rods generates 10-nm spherical particles having high alpha-helical content and lacking scrapie infectivity.

Authors:  D Riesner; K Kellings; K Post; H Wille; H Serban; D Groth; M A Baldwin; S B Prusiner
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

5.  Identification of a protein that purifies with the scrapie prion.

Authors:  D C Bolton; M P McKinley; S B Prusiner
Journal:  Science       Date:  1982-12-24       Impact factor: 47.728

6.  Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein.

Authors:  D Vilette; O Andreoletti; F Archer; M F Madelaine; J L Vilotte; S Lehmann; H Laude
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

7.  Transmission of the BSE agent to mice in the absence of detectable abnormal prion protein.

Authors:  C I Lasmézas; J P Deslys; O Robain; A Jaegly; V Beringue; J M Peyrin; J G Fournier; J J Hauw; J Rossier; D Dormont
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

8.  Replication of distinct scrapie prion isolates is region specific in brains of transgenic mice and hamsters.

Authors:  R Hecker; A Taraboulos; M Scott; K M Pan; S L Yang; M Torchia; K Jendroska; S J DeArmond; S B Prusiner
Journal:  Genes Dev       Date:  1992-07       Impact factor: 11.361

9.  Purified prion proteins and scrapie infectivity copartition into liposomes.

Authors:  R Gabizon; M P McKinley; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

Review 10.  Prions.

Authors:  S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

View more
  7 in total

1.  Direct evidence of generation and accumulation of β-sheet-rich prion protein in scrapie-infected neuroblastoma cells with human IgG1 antibody specific for β-form prion protein.

Authors:  Toshiya Kubota; Yuta Hamazoe; Shuhei Hashiguchi; Daisuke Ishibashi; Kazuyuki Akasaka; Noriyuki Nishida; Shigeru Katamine; Suehiro Sakaguchi; Ryota Kuroki; Toshihiro Nakashima; Kazuhisa Sugimura
Journal:  J Biol Chem       Date:  2012-02-22       Impact factor: 5.157

2.  Mammalian prions: tracking the infectious entities.

Authors:  Jimmy Savistchenko; Zaira E Arellano-Anaya; Olivier Andréoletti; Didier Vilette
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

3.  Prion strains are differentially released through the exosomal pathway.

Authors:  Zaira E Arellano-Anaya; Alvina Huor; Pascal Leblanc; Sylvain Lehmann; Monique Provansal; Graça Raposo; Olivier Andréoletti; Didier Vilette
Journal:  Cell Mol Life Sci       Date:  2014-09-18       Impact factor: 9.261

4.  A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds.

Authors:  Carol L Ladner-Keay; Li Ross; Rolando Perez-Pineiro; Lun Zhang; Trent C Bjorndahl; Neil Cashman; David S Wishart
Journal:  Prion       Date:  2018-10-09       Impact factor: 3.931

5.  A simple, versatile and sensitive cell-based assay for prions from various species.

Authors:  Zaira E Arellano-Anaya; Jimmy Savistchenko; Jacinthe Mathey; Alvina Huor; Caroline Lacroux; Olivier Andréoletti; Didier Vilette
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

6.  Heterogeneity of the Abnormal Prion Protein (PrPSc) of the Chandler Scrapie Strain.

Authors:  Kazuo Kasai; Yoshifumi Iwamaru; Kentaro Masujin; Morikazu Imamura; Shirou Mohri; Takashi Yokoyama
Journal:  Pathogens       Date:  2013-02-18

7.  Quaternary structure of pathological prion protein as a determining factor of strain-specific prion replication dynamics.

Authors:  Florent Laferrière; Philippe Tixador; Mohammed Moudjou; Jérôme Chapuis; Pierre Sibille; Laetitia Herzog; Fabienne Reine; Emilie Jaumain; Hubert Laude; Human Rezaei; Vincent Béringue
Journal:  PLoS Pathog       Date:  2013-10-10       Impact factor: 6.823

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.